Search

Your search keyword '"Ghesquieres, H."' showing total 20 results
Start Over Author "Ghesquieres, H." Publisher wiley
20 results on '"Ghesquieres, H."'

1. LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSE

Author

Nastoupil, L. J., primary, Kamdar, M., additional, Chavez, J. C., additional, Ghesquieres, H., additional, Ghosh, M., additional, Holmes, H., additional, López‐Guillermo, A., additional, Martínez‐López, J., additional, Novak, U., additional, Ribrag, V., additional, Roddie, C., additional, Waller, E. K., additional, Feldman, T., additional, Rosenthal, A. C., additional, Sauter, C., additional, von Bonin, M., additional, Karmali, R., additional, Montheard, S., additional, Previtali, A., additional, and Abramson, J., additional

Published
2023
Full Text
View/download PDF

2. COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA

Author

Hutchings, M., primary, Dickinson, M., additional, Carlo‐Stella, C., additional, Morschhauser, F., additional, Bosch, F., additional, Gritti, G., additional, Townsend, W., additional, Bartlett, N. L., additional, Cartron, G., additional, Ghesquieres, H., additional, Houot, R., additional, Walter, H., additional, Offner, F., additional, Christiansen, A., additional, Dimier, N., additional, Jamois, C., additional, Harrop, E., additional, Herter, S., additional, Hölzlwimmer, G., additional, Keelara, A., additional, Korfi, K., additional, Luong, J., additional, Mueller, C., additional, Mycroft, S., additional, Whayman, M., additional, Prieto, I., additional, Rukina, D., additional, and Lechner, K., additional

Published
2023
Full Text
View/download PDF

3. TRANSCEND FL: PHASE 2 STUDY RESULTS OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

Author

Morschhauser, F., primary, Dahiya, S., additional, Palomba, M. L., additional, Garcia‐Sancho, A. M., additional, Ortega, J. L. Reguera, additional, Kuruvilla, J., additional, Jager, U., additional, Cartron, G., additional, Izutsu, K., additional, Dreyling, M., additional, Kahl, B., additional, Ghesquieres, H., additional, Ardeshna, K., additional, Goto, H., additional, Barbui, A. M., additional, Abramson, J. S., additional, Borchmann, P., additional, Fleury, I., additional, Mielke, S., additional, Farazi, T., additional, Fasan, O., additional, Lymp, J., additional, Vedal, M., additional, Nishii, R., additional, Avilion, A., additional, Papuga, J., additional, and Nastoupil, L. J., additional

Published
2023
Full Text
View/download PDF

4. VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.

Author

Sarkozy, C., primary, Thieblemont, C., additional, Oberic, L., additional, Moreau, A., additional, Bouabdallah, K., additional, Damaj, G., additional, Gastine, T., additional, Ribrag, V., additional, Casasnovas, O., additional, Haioun, C., additional, Houot, R., additional, Jardin, F., additional, Van Den Neste, E., additional, Cheminant, M., additional, Morschhauser, F., additional, Callana, M., additional, Ghesquieres, H., additional, Gressin, R., additional, Hermine, O., additional, and Le Gouill, S., additional

Published
2023
Full Text
View/download PDF

5. Tandem haematopoietic stem cell transplantation versus single cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA

Author

Marouf, A., primary, Molinari, N., additional, Sibon, D., additional, Cottereau, A. S., additional, Kanoun, S., additional, Antoine, C., additional, Debureaux, P. E., additional, Cavalieri, D., additional, Fornecker, L. M., additional, Casasnovas, R. O., additional, Herbaux, C., additional, Amorim, S., additional, Rossi, C., additional, Bouscary, D., additional, Brice, P., additional, Ghesquieres, H., additional, Tamburini, J., additional, and Deau, B., additional

Published
2023
Full Text
View/download PDF

6. BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT IN PATIENTS WITH STAGE I/II CLASSICAL HODGKIN'S LYMPHOMA AND A POSITIVE FDG‐PET AFTER 2 CYCLES OF ABVD: A LYSA PHASE 2 STUDY

Author

Gastinne, T., primary, Bouabdallah, K., additional, Moatti, H., additional, Tessoulin, B., additional, Shiano del colella, J. M., additional, Lamy, T., additional, Casasnovas, O., additional, Borel, C., additional, Stamatoullas, A., additional, Gac, A. C., additional, Chaoui, D., additional, Feugier, P., additional, Delmer, A., additional, Bonnet, C., additional, Fornecker, Luc‐M., additional, Lazarovici, J., additional, Bras, F., additional, Ghesquieres, H., additional, Meignan, M., additional, Traverse Glehen, A., additional, and Brice, P., additional

Published
2021
Full Text
View/download PDF

7. OUTCOMES IN LATER‐LINES OF THERAPY FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: RESULTS FROM THE INTERNATIONAL SCHOLAR‐5 STUDY

Author

Ghione, P., primary, Ghesquieres, H., additional, Bobillo, S., additional, Patel, A. R., additional, Kanters, S., additional, Deighton, K., additional, Dong, H., additional, Yang, Y., additional, Ma, L., additional, Limbrick‐Oldfield, E. H., additional, Thornton Snider, J., additional, Wade, S. W., additional, Riberio, M. T., additional, Sudhindra, A., additional, Radford, J., additional, Palomba, M. L., additional, and Gribben, J., additional

Published
2021
Full Text
View/download PDF

8. AMAHRELIS : ADCETRIS MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN HODGKIN LYMPHOMA : A REAL LIFE STUDY FROM SFGMTC AND LYSA GROUPS

Author

Marouf, A., primary, Cottereau, A. S., additional, Kanoun, S., additional, Deschamps, P., additional, Franchi, P., additional, Meignan, M., additional, Sibon, D., additional, Gastinne, T., additional, Borel, C., additional, Hammoud, M., additional, Sicard, G., additional, Gille, R., additional, Cavalieri, D., additional, Stamatoullas, A., additional, Clement, L., additional, Lazarovici, J., additional, Chauchet, A., additional, Fornecker, L. M., additional, Amorin, S., additional, Rocquet, M., additional, Raus, N., additional, Burroni, B., additional, Rubio, M. T., additional, Casasnovas, O., additional, Cartron, G., additional, Bouscary, D., additional, Brice, P., additional, Ghesquieres, H., additional, Tamburini, J., additional, and Deau, B., additional

Published
2021
Full Text
View/download PDF

9. EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL

Author

Bologna, S, primary, Vander Borght, T, additional, Briere, J, additional, Ribrag, V, additional, Damaj, G. L, additional, Thieblemont, C, additional, Feugier, P, additional, Peyrade, F, additional, Lebras, L, additional, Coso, D, additional, Sibon, D, additional, Bonnet, C, additional, Morschhauser, F, additional, Ghesquieres, H, additional, Becker, S, additional, Olivier, P, additional, Fabiani, B, additional, Tilly, H, additional, Haioun, C, additional, and Bastie, J. N, additional

Published
2021
Full Text
View/download PDF

10. Relapsed / Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma

Author

Maurer, MJ, Jakobsen, LH, Mwangi, R, Schmitz, N, Farooq, U, Flowers, CR, de Nully Brown, P, Thompson, CA, Frederiksen, H, Cunningham, D, Jorgensen, J, Poeschel, V, Nowakowski, G, Seymour, JF, Merli, F, Haioun, C, Ghesquieres, H, Ziepert, M, Tilly, H, Salles, G, Shi, Q, El-Galaly, TC, Habermann, TM, Maurer, MJ, Jakobsen, LH, Mwangi, R, Schmitz, N, Farooq, U, Flowers, CR, de Nully Brown, P, Thompson, CA, Frederiksen, H, Cunningham, D, Jorgensen, J, Poeschel, V, Nowakowski, G, Seymour, JF, Merli, F, Haioun, C, Ghesquieres, H, Ziepert, M, Tilly, H, Salles, G, Shi, Q, El-Galaly, TC, and Habermann, TM

Abstract

Disease progression after frontline therapy for Diffuse large B-cell lymphoma (DLBCL) is a clinically significant event. Patients who experience early progression or have refractory disease have especially poor outcomes. Simple, clinically applicable prognostic tools are needed for selecting patients for consideration for novel therapies and prognostication in the relapsed/refractory (R/R) setting. Model building was performed in patients from the Surrogate endpoints in aggressive lymphoma (SEAL) consortium with disease progression after frontline immunochemotherapy. The primary endpoint was overall survival (OS) measured from date of progression. Validation was performed in the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource (MER) and Danish National Lymphoma Register (LYFO) cohorts. Model performance was assessed using time-dependent concordance indices (c-statistic) and calibration with metrics evaluated at 2 years from progression. Note, 1234 of 5112 patients treated with frontline immunochemotherapy in the SEAL consortium developed progressive disease. Time to progression on immunochemotherapy and age at progression were strongly associated with post-progression OS (both p < 0.001). A prognostic model was developed incorporating spline fit for both variables. The model had good concordance in the discovery (0.67) and validation sets (LYFO c = 0.64, MER c = 0.68) with generally good calibration. Time to progression on frontline therapy is strongly associated with post-progression OS in DLBCL. We developed and validated a simple to apply clinical prognostic tool in the R/R setting. The useful prediction of expected outcomes in R/R DLBCL and can inform treatment decisions such as considerations for CAR-T therapy as well as trial designs. The model is available in smartphone-based point of care applications.

Published
2021

11. Commercialanti-CD19 CART cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center

Author

Sesques, P, Ferrant, E, Safar, V, Wallet, F, Tordo, J, Dhomps, A, Karlin, L, Brisou, G, Vercasson, M, Hospital-Gustem, C, Schwiertz, V, Ranchon, F, Rioufol, C, Choquet, M, Sujobert, P, Ghergus, D, Bouafia, F, Golfier, C, Lequeu, H, Lazareth, A, Novelli, S, Devic, P, Glehen, AT, Viel, S, Venet, F, Mialou, V, Hequet, O, Chauchet, A, Arkam, Y, Nicolas-Virelizier, E, Peyrade, F, Cavalieri, D, Ader, F, Ghesquieres, H, Salles, G, and Bachy, E

Abstract

Two autologous anti-CD19 chimeric antigen receptors (CAR) T cells (axicabtagene ciloleucel [axi-cel] and tisagenlecleucel [tisa-cel]) are commercially approved in Europe for relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). We performed a retrospective study to evaluate patterns of use, efficacy and safety for axi-cel and tisa-cel. Data from 70 patients who underwent apheresis for commercial CAR T cells between January 2018 and November 2019 in our institution were retrospectively collected. Sixty-one patients were infused. The median age at infusion was 59 years old (range 27-75 years). The median number of prior therapies was 3 (range, 2-6). The overall response rates (ORRs) at 1 month and 3 months were 63% and 45%, respectively, with 48% and 39% achieving a complete response (CR), respectively. After a median follow-up after infusion of 5.7 months, the median progression-free survival (PFS) was 3.0 months (95% CI, 2.8-8.8 months), and the median overall survival (OS) was 11.8 months (95% CI, 6.0-12.6 months). In multivariate analysis, factors associated with poor PFS were the number of previous lines of treatment before CAR T cells (>= 4) (P= .010) and a C reactive protein (CRP) value >30 mg/L at the time of lymphodepletion (P 30 mg/L (P= .009). Cytokine release syndrome (CRS) of any grade occurred in 85% of patients, including 8% of patients with CRS of grade 3 or higher. Immune cell-associated neurotoxicity syndrome (ICANS) of any grade occurred in 28% of patients, including 10% of patients with ICANS of grade 3 or higher. Regarding efficacy and safety, no significant difference was found between axi-cel and tisa-cel. This analysis describes one of the largest real-life cohorts of patients treated with axi-cel and tisa-cel for R/R aggressive B cell lymphoma in Europe.

Published
2020

12. Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes

Author

Din, L, Sheikh, M, Kosaraju, N, Smedby, KE, Bernatsky, S, Berndt, S, Skibola, CF, Nieters, A, Wang, S, McKay, JD, Cocco, P, Maynadie, M, Foretova, L, Staines, A, Mack, TM, de Sanjose, S, Vyse, TJ, Padyukov, L, Monnereau, A, Arslan, AA, Moore, A, Brooks-Wilson, AR, Novak, AJ, Glimelius, B, Birmann, BM, Link, BK, Stewart, C, Vajdic, CM, Haioun, C, Magnani, C, Conti, D, Cox, DG, Casabonne, D, Albanes, D, Kane, E, Roman, E, Muzi, G, Salles, G, Giles, GG, Adami, H-O, Ghesquieres, H, De Vivo, I, Clavel, J, Cerhan, JR, Spinelli, JJ, Hofmann, J, Vijai, J, Curtin, K, Costenbader, KH, Onel, K, Offit, K, Teras, LR, Morton, L, Conde, L, Miligi, L, Melbye, M, Ennas, MG, Liebow, M, Purdue, MP, Glenn, M, Southey, MC, Din, M, Rothman, N, Camp, NJ, Doo, NW, Becker, N, Pradhan, N, Bracci, PM, Boffetta, P, Vineis, P, Brennan, P, Kraft, P, Lan, Q, Severson, RK, Vermeulen, RCH, Milne, RL, Kaaks, R, Travis, RC, Weinstein, SJ, Chanock, SJ, Ansell, SM, Slager, SL, Zheng, T, Zhang, Y, Benavente, Y, Taub, Z, Madireddy, L, Gourraud, P-A, Oksenberg, JR, Cozen, W, Hjalgrim, H, Khankhanian, P, Din, L, Sheikh, M, Kosaraju, N, Smedby, KE, Bernatsky, S, Berndt, S, Skibola, CF, Nieters, A, Wang, S, McKay, JD, Cocco, P, Maynadie, M, Foretova, L, Staines, A, Mack, TM, de Sanjose, S, Vyse, TJ, Padyukov, L, Monnereau, A, Arslan, AA, Moore, A, Brooks-Wilson, AR, Novak, AJ, Glimelius, B, Birmann, BM, Link, BK, Stewart, C, Vajdic, CM, Haioun, C, Magnani, C, Conti, D, Cox, DG, Casabonne, D, Albanes, D, Kane, E, Roman, E, Muzi, G, Salles, G, Giles, GG, Adami, H-O, Ghesquieres, H, De Vivo, I, Clavel, J, Cerhan, JR, Spinelli, JJ, Hofmann, J, Vijai, J, Curtin, K, Costenbader, KH, Onel, K, Offit, K, Teras, LR, Morton, L, Conde, L, Miligi, L, Melbye, M, Ennas, MG, Liebow, M, Purdue, MP, Glenn, M, Southey, MC, Din, M, Rothman, N, Camp, NJ, Doo, NW, Becker, N, Pradhan, N, Bracci, PM, Boffetta, P, Vineis, P, Brennan, P, Kraft, P, Lan, Q, Severson, RK, Vermeulen, RCH, Milne, RL, Kaaks, R, Travis, RC, Weinstein, SJ, Chanock, SJ, Ansell, SM, Slager, SL, Zheng, T, Zhang, Y, Benavente, Y, Taub, Z, Madireddy, L, Gourraud, P-A, Oksenberg, JR, Cozen, W, Hjalgrim, H, and Khankhanian, P

Abstract

Epidemiologic studies show an increased risk of non-Hodgkin lymphoma (NHL) in patients with autoimmune disease (AD), due to a combination of shared environmental factors and/or genetic factors, or a causative cascade: chronic inflammation/antigen-stimulation in one disease leads to another. Here we assess shared genetic risk in genome-wide-association-studies (GWAS). Secondary analysis of GWAS of NHL subtypes (chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma) and ADs (rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis). Shared genetic risk was assessed by (a) description of regional genetic of overlap, (b) polygenic risk score (PRS), (c)"diseasome", (d)meta-analysis. Descriptive analysis revealed few shared genetic factors between each AD and each NHL subtype. The PRS of ADs were not increased in NHL patients (nor vice versa). In the diseasome, NHLs shared more genetic etiology with ADs than solid cancers (p = .0041). A meta-analysis (combing AD with NHL) implicated genes of apoptosis and telomere length. This GWAS-based analysis four NHL subtypes and three ADs revealed few weakly-associated shared loci, explaining little total risk. This suggests common genetic variation, as assessed by GWAS in these sample sizes, may not be the primary explanation for the link between these ADs and NHLs.

Published
2019

13. POOLED RESULTS OF THREE ANNUAL COHORTS FROM AN OBSERVATIONAL PROSPECTIVE STUDY DESCRIBING BRENTUXIMAB VEDOTIN USE IN ROUTINE PRACTICE IN FRANCE FOR HODGKIN LYMPHOMA: INTERIM ANALYSIS

Author

Sibon, D., primary, Quittet, P., additional, Borel, C., additional, Stamatoullas, A., additional, Franchi-Rezgui, P., additional, Ghesquieres, H., additional, Dulery, R., additional, Benbrahim, O., additional, Hammoud, M., additional, Durot, E., additional, De Guibert, S., additional, Coulibaly, C., additional, Casasnovas, O., additional, Bouabdallah, R., additional, and Brice, P., additional

Published
2019
Full Text
View/download PDF

14. COMPARISON OF CLINICAL SCORING SYSTEMS IN AGGRESSIVE B-CELL LYMPHOMAS (BCL): AN INDIVIDUAL PATIENT-LEVEL ANALYSIS ACROSS INTERNATIONAL TRIAL

Author

Schmitz, N.F., primary, Dixon, J.G., additional, Salles, G., additional, Wall, A., additional, Cunningham, D., additional, Poeschel, V., additional, Haioun, C., additional, Tilly, H., additional, Ghesquieres, H., additional, Ziepert, M., additional, Flament, J., additional, Flowers, C., additional, Shi, Q., additional, and Ruppert, A.S., additional

Published
2019
Full Text
View/download PDF

16. ROLE OF UP-FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMAS: a PROPENSITY SCORE MATCHING ANALYSIS OF PATIENTS FROM LYSA CENTERS

Author

Fossard, G., primary, Broussais, F., additional, Coelho, I., additional, Bailly, S., additional, Nicolas-Virelizier, E., additional, Toussaint, E., additional, Lancesseur, C., additional, Lebras, F., additional, Willems, E., additional, Tchernonog, E., additional, Delarue, R., additional, Gressin, R., additional, Chauchet, A., additional, Gyan, E., additional, Cartron, G., additional, Bonnet, C., additional, Haioun, C., additional, Damaj, G., additional, Gaulard, P., additional, Fornecker, L., additional, Ghesquieres, H., additional, Tournilhac, O., additional, Gomes Da Silva, M., additional, Bouabdallah, R., additional, Salles, G., additional, and Bachy, E., additional

Published
2017
Full Text
View/download PDF

17. CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS

Author

Sarkozy, C., primary, Link, B., additional, Ghesquieres, H., additional, Maurer, M., additional, Nicolas-Virelizier, E., additional, Thompson, C., additional, Traverse-Glehen, A., additional, Feldman, A., additional, Allmer, C., additional, Slager, S., additional, Ansell, S., additional, Habermann, T., additional, Bachy, E., additional, Cerhan, J., additional, and Salles, G., additional

Published
2017
Full Text
View/download PDF

18. TUMOR GENOMIC COPY NUMBER ABNORMALITIES ANALYZED BY HIGH RESOLUTION SNP ARRAY IMPACT OUTCOME OF PRIMARY CNS LYMPHOMA: A RETROSPECTIVE ANALYSIS ON 68 PATIENTS

Author

Ghesquieres, H., primary, Tesson, B., additional, Courtois-Cox, S., additional, Boyault, S., additional, Nicolas-Virelizier, E., additional, Carrere, M., additional, Traverse-Glehen, A., additional, Perrin, C., additional, Chassagne-Clement, C., additional, Jouanneau, E., additional, Salles, G., additional, Honnorat, J., additional, Blay, J., additional, and Meyronet, D., additional

Published
2017
Full Text
View/download PDF

19. THE 5-YEAR FOLLOW-UP RESULTS OF THE C5R PROTOCOL WITH RITUXIMAB AND INTRATHECAL LIPOSOMAL CYTARABINE FOR PRIMARY CNS LYMPHOMA: A PROSPECTIVE PHASE 2 STUDY OF THE LYSA

Author

Ghesquieres, H., primary, Tilly, H., additional, Sonet, A., additional, Dupuis, J., additional, Nicolas-Virelizier, E., additional, Andre, M., additional, Trullemans, F., additional, Eisenmann, J., additional, Delarue, R., additional, Fleck, E., additional, Morschhauser, F., additional, and Blay, J., additional

Published
2017
Full Text
View/download PDF

20. NON-MEDIASTINAL CASES OF GREY ZONE LYMPHOMA: A PATHOLOGICAL AND CLINICAL SERIES OF 17 CASES FROM THE LYSA

Author

Sarkozy, C., primary, Mottok, A., additional, Ghesquieres, H., additional, Herbeaux, C., additional, Ben-Neriah, S., additional, Chassagne-Clément, C., additional, Copie-Bergmann, C., additional, Picquenot, J., additional, Cornillon, J., additional, Lemal, R., additional, Bonnet, A., additional, Manson, G., additional, Golfier, C., additional, Michallet, A., additional, Salles, G., additional, Steidl, C., additional, and Traverse-Glehen, A., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results